Catalyst Firdapse Gets Orphan Status For Myasthenia Gravis
Zacks Investment Research | Sep 05, 2016 09:09PM ET
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced that the FDA has granted orphan drug designation to Firdapse (amifampridine phosphate) for the treatment of myasthenia gravis.
Orphan drug designation is given to drugs being developed for rare diseases/disorders that affect less than 200,000 people in the U.S. Incentives that come with orphan drug status include close guidance from the FDA that may accelerate the time to marketing approval, orphan drug grants, tax credits and a period of market exclusivity upon marketing approval.
As per the information provided by the company, myasthenia gravis caused by antibodies to the muscle-specific kinase (MuSK-MG) is a rare disease, estimated to affect 5–8% of all myasthenia gravis patients, which means approximately 4,500 patients in the U.S.
The company is currently supporting an investigator-sponsored, randomized, double-blinded, placebo-controlled study evaluating Firdapse for the treatment of patients with MuSK-MG. Top-line results from this study are expected in early 2017.
Assuming positive results from the trial and availability of funds, Catalyst Pharma plans to initiate a registration quality trial in the U.S. to evaluate Firdapse in the treatment of MuSK-MG.
We remind investors that the FDA has granted Breakthrough Therapy Designation to Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Firdapse also enjoys orphan drug status for LEMS and congenital myasthenic syndromes (CMS) in the U.S. Moreover, the drug is approved in Europe for the symptomatic treatment of adults with LEMS.
Firdapse’s approval in the U.S. is critical to the company’s success. Earlier this year, the company received a refusal-to-file letter from the FDA in connection with its NDA for Firdapse. The agency had determined that the company’s NDA was insufficient after a preliminary review. Consequently, the company was required to conduct additional studies as per the agency’s requirements, which translated into additional costs.
Currently, Catalyst Pharma carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , Corcept Therapeutics Incorporated (NASDAQ:CORT) and ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) . All of these stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.